Hernández-Cruz, Blanca
Kiltz, Uta
Avouac, Jérôme
Treuer, Tamas
Haladyj, Ewa
Gerwien, Jens
Gupta, Chandreyee Dutta
Conti, Fabrizio
Funding for this research was provided by:
Eli Lilly and Company
Article History
Received: 16 June 2023
Accepted: 3 August 2023
First Online: 16 September 2023
Declarations
:
: Tamas Treuer: Tamas Treuer is an employee and shareholder of Eli Lilly and Company. Ewa Haladyj: Ewa Haladyj is an employee and shareholder of Eli Lilly and Company. Jens Gerwien: Jens Gerwien is an employee and shareholder of Eli Lilly and Company. Chandreyee Dutta Gupta: Chandreyee Dutta Gupta is an employee and shareholder of Eli Lilly and Company. Blanca Hernández-Cruz: Grant and research support and consultancy fees in the last 3 years from AbbVie, Amgen, BMS, Eli Lilly, Fresenius, Grunnenta, STAD, and Gilead. Uta Kiltz: Grant and research support and consultancy fees from AbbVie, Amgen, Biocad, Biogen, BMS, Chugai, Eli Lilly, Fresenius, Gilead, Grünenthal, GSK, Hexal, Janssen, MSD, Novartis, onkowoessen.de, Pfizer, Roche, UCB, and Viatris.. Jérôme Avouac: Honoraria from Pfizer, Lilly, Bristol Myers Squibb, UCB, Roche, Nordic Pharma, Novartis, Sanofi, Boehringer, AbbVie, Chugai, Galapagos, Biogen, Fresenius Kabi, Sandoz, and AstraZeneca. Research grants: Pfizer, Bristol Myers Squibb, Fresenius Kabi, Novartis, Nordic Pharma, Galapagos. Fabrizio Conti: Speaker fee: Eli Lilly, Biogen, BMS, Galapagos, AbbVie, Pfizer, UCB.
: This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.